Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
about
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic reviewEffect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan AfricaCurrent epidemiology of Pneumocystis pneumoniaCotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority TrialPneumocystis jirovecii pneumonia in Latin America. A public health problem?Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.Performance measures for guidelines on preventing opportunistic infections in patients infected with human immunodeficiency virus.Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3.Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management.Clinical indicators of immune restoration following highly active antiretroviral therapy.The pharmacogenomics of HIV therapy.HIV viral suppression in the era of antiretroviral therapyHIV-1 and bacterial pneumonia in the era of antiretroviral therapy.Recommendations for the treatment of fungal pneumonias.The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia.2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Colonization by Pneumocystis jirovecii and its role in disease.Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational databaseThe effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trialTherapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review.Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects.Molecular detection of pneumocystis jirovecii in patients with respiratory tract infections.Genotyping of Pneumocystis jirovecii isolates from Chinese HIV-infected patients based on nucleotide sequence variations in the internal transcribed spacer regions of rRNA genes.Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy.2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis.Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection.
P2860
Q26829541-4EB444F5-1F4D-4213-AE6B-03FD38856905Q28084902-355FE12C-9705-49D8-B231-55F0A9D08B3CQ28289603-B2254C64-E81B-4300-9D1A-08596E2F3559Q28552031-E3771151-9FF6-476C-AD10-7FF2B0430179Q30431684-E7117C36-3C47-452C-8052-6E8F4BE8FBFFQ33584240-F5B9C863-8562-4A56-BB36-98E7DE400F86Q33894498-041B1353-B48E-42C0-8672-22C63FC06E88Q33894511-21506D41-A255-47F8-978E-F1CE9886B4E1Q33969487-4AD83734-941A-4927-845A-1405E7EF74ACQ34004404-8FF8C689-2A0F-4F83-9C0A-9348FFE45EA6Q34085884-C5E6D7A1-AFC0-4AAD-8C45-56D918A9F1DFQ34092112-50DD6C6C-7EF3-4020-925D-D0223F0A9130Q34341001-96C94183-91B2-47E8-8D29-A75D25CDF45FQ34459389-E793B560-BC81-4A4F-B966-AA5343EF5D7BQ34461371-801E17DE-7297-4573-A14C-44568CDCA9BCQ34574033-E9399011-AE6B-4A6C-8424-3DFA5969CB97Q35059337-342ABD57-79F4-4AF8-BDC3-067E734C0295Q35095031-6B08B2B5-183F-4C7B-B46B-078B7AE1E2E7Q35183728-2861BA23-67E6-4E3A-BA7C-4EB8689E81FDQ35186822-0AB24CC4-FB2E-470C-863B-9578BE315042Q35614631-D917C960-1BD8-4EA2-871B-3E6FB969DF22Q35940586-421BF428-5D14-4780-A1FC-A0F9D52FA9C4Q35967212-672C6078-A243-401F-A7FF-CF76BC69E24EQ36504556-A3C7CCFD-452C-4612-B92B-72A6E3F9A058Q36517673-F296B427-DECF-488C-BCA9-F5152CB0DDA0Q37108386-A3663C20-747F-480B-8EF7-60D0E90714D2Q37180338-C08A5A69-4277-453C-837E-5CB93A207C0BQ39404140-75001ED1-4568-4680-854B-D6A16E1CAB62Q39758104-966ED1C3-9137-4C31-8C6B-4096969421EEQ41674713-D2417DF0-1F74-4961-84DE-EBB2BE33E52CQ43453614-7691B728-12DF-484A-A9C0-943FDDEDEB66Q43599627-3F042EE5-DE0A-4132-9D7C-1543AAAEF616Q43818097-6762DF59-F9CC-4E38-9FDF-2BFAE62593BAQ43818117-69F19FB6-6EE7-4D9C-A512-E01C4026438FQ44382493-536C798B-D15B-4A0C-8202-0B8E8EA6294BQ44616568-1301E677-C6FE-44D8-8619-C2EAABE90DF9Q44794025-2F113651-ABD7-44FE-9D75-B6C2B58654CBQ45734909-58ACE4D6-78E0-4E07-A2EB-1E74FE021DFAQ45735357-813CAF2A-9B7E-41D2-BFBA-4867CFA953CDQ53514004-1CD167AC-28C6-452C-84AA-E94CE329A3B7
P2860
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@en
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@nl
type
label
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@en
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@nl
prefLabel
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@en
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@nl
P2093
P1433
P1476
Discontinuation of Pneumocysti ...... fection. EuroSIDA Study Group.
@en
P2093
A N Phillips
A d'Arminio Monforte
B Ledergerber
G J Weverling
J D Lundgren
J Gonzáles-Lahoz
P304
P356
10.1016/S0140-6736(99)03287-0
P407
P577
1999-04-01T00:00:00Z